Total and H‐specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration
Authors' conclusion
Neither total nor H-specific GDF-15 levels are affected by Lira or N/B treatment in patients with overweight or obesity.
Study context
- Population
- Individuals with overweight or obesity without T1D or T2D; treatment assigned by comorbidities, cost and method of administration
- Participants
- 42 individuals
- Comparison
- Liraglutide 3 mg vs naltrexone/bupropion 32/360 mg
- Primary endpoint
- Total and H-specific GDF-15 levels, fasting and every 30 min for 3 h after a standardized mixed meal
- Follow-up
- Baseline, 3 and 6 months
Methodological detailstwo-arm, parallel
- Two-arm
- Parallel
Primary result
As reported in the abstract
Total and H-specific GDF-15 levels
- Total and H-specific GDF-15 levels did not change significantly during the mixed meal vs pre-meal values in all participants at baseline, 3 and 6 months
- No statistical significance by subgroup (liraglutide (Lira) vs N/B)
- No significant differences between treatment groups in postprandial AUC or incremental AUC of total and H-specific GDF-15 at baseline or follow-up
Further findings
Weight reduction, all participants
- Weight reduction at Month 3
- 9.29 ± 5.34 kg
- Weight reduction at Month 6
- 11.52 ± 7.52 kg
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Total and H‐specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration. Diabetes Obes Metab. Published 17 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →